Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Andrew J. Wagner, William D. Tap, Sebastian Bauer, Jean Yves Blay, Jayesh Desai, Hans Gelderblom, Emanuela Palmerini, Christopher W. Ryan, Charles Peterfy, John H. Healey, Michiel A. J. van de Sande, Meng Qian, Dale E. Shuster, Abdul Waheed Rajper, Xin Ye, Kristen M. Tecson, Margaret Wooddell, Silvia Stacchiotti (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. , 30(7), DOI: https://doi.org/10.1093/oncolo/oyae345.
Article20 days agoLong-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.
Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap (2025). Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.11558.
Article20 days agoPhase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).
Andrew J. Wagner, Silvia Stacchiotti, C. Debruyne, Abdulazeez Salawu, Jean Yves Blay, Fernando Augusto Batista Campos, Hiroaki Hiraga, Antoine Italiano, Akira Kawai, Ganessan Kichenadasse, Yoshihiro Nishida, Seth M. Pollack, Zhe Qu, Evinaa Sellaiah, Ilona Tala, Gabriel Tinoco, Jonathan C. Trent, Karina Costa Maia Vianna, Kan Yonemori, William D. Tap (2025). Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps11582.
Article20 days agoGuidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment
César Serrano, Sebastian Bauer, Jean Yves Blay, Paolo G. Casali, Carlo María Cicala, Angelo Paolo Dei Tos, Antonia Digklia, Hans Gelderblom, Antoine Italiano, Robin L. Jones, Bernd Kasper, Anastasios Kyriazoglou, François Le Loarer, Javier Martín‐Broto, Andrea Napolitano, Piotr Rutkowski, Silvia Stacchiotti, William D. Tap, David J. Thomas, Khin Thway, Claudia Valverde, Winette T.A. van der Graaf, Eva Wardelmann, Judith V.M.G. Bovée (2025). Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment. , 11(12), DOI: https://doi.org/10.1001/jamaoncol.2025.3608.
Article20 days agoEfficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.
William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom (2024). Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.11500.
Article20 days ago